
### [NCIT:C43584](http://purl.obolibrary.org/obo/NCIT_C43584)
**Label:** Rectosigmoid Adenocarcinoma

**Subclasses:** [NCIT:C43592](http://purl.obolibrary.org/obo/NCIT_C43592) (Rectosigmoid Mucinous Adenocarcinoma), [NCIT:C43593](http://purl.obolibrary.org/obo/NCIT_C43593) (Rectosigmoid Signet Ring Cell Carcinoma), 

**Class expressions from DL-Learner:**

- [NCIT:C5034](http://purl.obolibrary.org/obo/NCIT_C5034) (Disturbance in Bowel Function) and (not ([NCIT:C2987](http://purl.obolibrary.org/obo/NCIT_C2987) (Diarrhea))) 70.00%
- [NCIT:C100104](http://purl.obolibrary.org/obo/NCIT_C100104) (Sign or Symptom) 63.09%
- [NCIT:C5034](http://purl.obolibrary.org/obo/NCIT_C5034) (Disturbance in Bowel Function) 60.82%
- [NCIT:C5034](http://purl.obolibrary.org/obo/NCIT_C5034) (Disturbance in Bowel Function) and (not ([NCIT:C39091](http://purl.obolibrary.org/obo/NCIT_C39091) (Corticosteroid Cardioprotection Pathway))) 60.82%
- [NCIT:C5034](http://purl.obolibrary.org/obo/NCIT_C5034) (Disturbance in Bowel Function) and (not ([NCIT:C39088](http://purl.obolibrary.org/obo/NCIT_C39088) (G2/M Checkpoint Pathway))) 60.82%
- [NCIT:C5034](http://purl.obolibrary.org/obo/NCIT_C5034) (Disturbance in Bowel Function) and (not ([NCIT:C39079](http://purl.obolibrary.org/obo/NCIT_C39079) (Fc Epsilon Receptor I Signaling Pathway BioCarta))) 60.82%
- [NCIT:C5034](http://purl.obolibrary.org/obo/NCIT_C5034) (Disturbance in Bowel Function) and (not ([NCIT:C39072](http://purl.obolibrary.org/obo/NCIT_C39072) (Erk1/Erk2 MAPK Signaling Pathway))) 60.82%
- [NCIT:C5034](http://purl.obolibrary.org/obo/NCIT_C5034) (Disturbance in Bowel Function) and (not ([NCIT:C39071](http://purl.obolibrary.org/obo/NCIT_C39071) (Neuronal Survival Pathway))) 60.82%
- [NCIT:C5034](http://purl.obolibrary.org/obo/NCIT_C5034) (Disturbance in Bowel Function) and (not ([NCIT:C39069](http://purl.obolibrary.org/obo/NCIT_C39069) (ErbB3 Receptor Recycling Pathway))) 60.82%
- [NCIT:C5034](http://purl.obolibrary.org/obo/NCIT_C5034) (Disturbance in Bowel Function) and (not ([NCIT:C39067](http://purl.obolibrary.org/obo/NCIT_C39067) (EPO Signaling Pathway))) 60.82%
- [NCIT:C5034](http://purl.obolibrary.org/obo/NCIT_C5034) (Disturbance in Bowel Function) and (not ([NCIT:C39066](http://purl.obolibrary.org/obo/NCIT_C39066) (Erythropoietin Neuroprotection Pathway))) 60.82%
- [NCIT:C5034](http://purl.obolibrary.org/obo/NCIT_C5034) (Disturbance in Bowel Function) and (not ([NCIT:C39059](http://purl.obolibrary.org/obo/NCIT_C39059) (Map Kinase Inactivation of SMRT Corepressor Pathway))) 60.82%
- [NCIT:C5034](http://purl.obolibrary.org/obo/NCIT_C5034) (Disturbance in Bowel Function) and (not ([NCIT:C39058](http://purl.obolibrary.org/obo/NCIT_C39058) (EGF Signaling Pathway))) 60.82%
- [NCIT:C5034](http://purl.obolibrary.org/obo/NCIT_C5034) (Disturbance in Bowel Function) and (not ([NCIT:C39056](http://purl.obolibrary.org/obo/NCIT_C39056) (Vesicle Transport Pathway))) 60.82%
- [NCIT:C5034](http://purl.obolibrary.org/obo/NCIT_C5034) (Disturbance in Bowel Function) and (not ([NCIT:C39055](http://purl.obolibrary.org/obo/NCIT_C39055) (Phospholipid Signaling Pathway))) 60.82%


